Cargando…
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple ups...
Autores principales: | Bao, Lei, Zhu, Ping, Mou, Yuan, Song, Yinhong, Qin, Ye |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360200/ https://www.ncbi.nlm.nih.gov/pubmed/37483603 http://dx.doi.org/10.3389/fimmu.2023.1214675 |
Ejemplares similares
-
Immunotherapies targeting tumor vasculature: challenges and opportunities
por: Dianat-Moghadam, Hassan, et al.
Publicado: (2023) -
Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023) -
Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch
por: Tu, Wen Juan, et al.
Publicado: (2020) -
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
por: Kouidhi, Soumaya, et al.
Publicado: (2018) -
Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
por: Xie, Hongyu, et al.
Publicado: (2021)